TVTX Stock Recent News

SAN DIEGO--(BUSINESS WIRE)-- #Inrareforlife--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare.

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Tyler Van Buren - TD Cowen Vamil Davin - Guggenheim Anupam Rama - JPMorgan Laura Chico - Wedbush Securities Liisa Bayko - Evercore Greg Harrison - Scotiabank Maury Raycroft - Jefferies Prakhar Agrawal - Cantor Jason Zemansky - Bank of America Operator Good afternoon, and welcome to the Travere Therapeutics First Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded.

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.76 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)-- #1Q25earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. “As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the year reflects this leadership – in the first quarter, we delivered 13% sequential net sales growth for FILSPARI in the U.S., driven by sustained d.

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the Euro.

European Commission converts conditional approval of FILSPARI (sparsentan)  into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025 EU approval is based on the complete data set from the phase-III PROTECT study ST. GALLEN, Switzerland and SAN DIEGO , April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

SAN DIEGO--(BUSINESS WIRE)-- #1Q25Earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Fo.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS.